Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 2-Reference-Cited by-同舟云学术

Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 2

Published:2020-01 Issue:1 Volume:109 Page:353-363
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Hu Yue,Toth Ronald T.,Joshi Sangeeta B.,Esfandiary Reza,Middaugh C. Russell,Volkin David B.,Weis David D.

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference57 articles.

1. High-Concentration Monoclonal Antibody Formulations;Armstrong,2013

2. Challenges in the development of high protein concentration formulations;Shire;J Pharm Sci,2004

3. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies;Gibson;J Pharm Sci,2011

4. Characterization of excipient effects on reversible self-association, flexibility, and solution properties of an IgG1 monoclonal antibody at high concentrations: part 1 (Companion Manuscript);Hu;J Pharm Sci,2019

5. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution;Liu;J Pharm Sci,2005

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stability of Protein Pharmaceuticals: Recent Advances;Pharmaceutical Research;2024-06-27

2. Interaction between preservatives and a monoclonal antibody in support of multidose formulation development;International Journal of Pharmaceutics;2023-12

3. A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations;mAbs;2023-05-27

4. Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?;Journal of Pharmaceutical Sciences;2021-11

5. Pragmatic mAb lead molecule engineering from a developability perspective;Biotechnology and Bioengineering;2021-06-24